Edition:
India

Neurotrope Inc (NTRP.OQ)

NTRP.OQ on NASDAQ Stock Exchange Capital Market

0.84USD
20 Sep 2019
Change (% chg)

$-0.08 (-8.37%)
Prev Close
$0.92
Open
$0.92
Day's High
$0.92
Day's Low
$0.84
Volume
125,969
Avg. Vol
58,911
52-wk High
$9.00
52-wk Low
$0.79

Latest Key Developments (Source: Significant Developments)

Neurotrope Announces $22.5 Mln Registered Direct Offering
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Neurotrope Inc ::NEUROTROPE ANNOUNCES $22.5 MILLION REGISTERED DIRECT OFFERING.NEUROTROPE INC - ANNOUNCED PRICING OF REGISTERED DIRECT OFFERING OF 5.0 MILLION SHARES OF COMMON STOCK.NEUROTROPE - EACH SHARE OF COMMON STOCK IS BEING SOLD TOGETHER WITH WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK FOR COMBINED PURCHASE PRICE OF $4.495.  Full Article

Neurotrope Provides Business Update And Reports Q2 2018 Financial Results
Monday, 13 Aug 2018 

Aug 13 (Reuters) - Neurotrope Inc ::NEUROTROPE PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.NEUROTROPE INC - AS OF JUNE 30, 2018, COMPANY HAD APPROXIMATELY $11.8 MILLION OF CASH AND CASH EQUIVALENTS.  Full Article

Neurotrope Inc - On May 4 Neurotrope Bioscience Executed A Services Agreement With Worldwide Clinical Trials
Friday, 11 May 2018 

May 10 (Reuters) - Neurotrope Inc ::NEUROTROPE INC - ON MAY 4 NEUROTROPE BIOSCIENCE EXECUTED A SERVICES AGREEMENT WITH WORLDWIDE CLINICAL TRIALS.NEUROTROPE - DEAL RELATES TO SERVICES FOR CONFIRMATORY PHASE 2 STUDY OF BRYOSTATIN IN TREATMENT OF MODERATELY SEVERE TO SEVERE ALZHEIMERS DISEASE.NEUROTROPE INC - NEUROTROPE AND NEUROTROPE BIOSCIENCE EXPECT THAT FIRST STUDY SITE WILL BE INITIATED DURING Q2 OF 2018.NEUROTROPE INC - PER AGREEMENT TOTAL ESTIMATED BUDGET FOR SERVICES, INCLUDING PASS-THROUGH COSTS, IS APPROXIMATELY $6.9 MILLION.  Full Article

Neurotrope Appoints Charles S. Ryan As CEO
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Neurotrope Inc ::NEUROTROPE APPOINTS CHARLES S. RYAN AS CHIEF EXECUTIVE OFFICER.NEUROTROPE INC - ‍ APPOINTMENT OF CHARLES RYAN FOLLOWS RESIGNATION OF SUSANNE WILKE, PHD, AS CHIEF EXECUTIVE OFFICER AND DIRECTOR​.NEUROTROPE INC - RYAN BECOMES A DIRECTOR OF COMPANY EFFECTIVE IMMEDIATELY AND WILL ASSUME HIS RESPONSIBILITIES AS CEO EFFECTIVE FEBRUARY 15, 2018.  Full Article

Neurotrope shares crash after Alzheimer's drug fails in trial

Drug developer Neurotrope Inc's shares tumbled nearly 80% on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study.